TEVA PHARMACEUTICAL INDUSTRIES LTD·4

Nov 2, 8:55 AM ET

Schultz Kare 4

4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Nov 2, 2022

Insider Transaction Report

Form 4
Period: 2022-11-01
Schultz Kare
DirectorPresident and CEO
Transactions
  • Exercise/Conversion

    Ordinary Shares

    2022-11-01+116,3891,542,471 total
  • Exercise/Conversion

    Restricted Share Units

    2022-11-01116,3890 total
    Ordinary Shares (116,389 underlying)
Footnotes (3)
  • [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  • [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  • [F3]Restricted share units were granted on November 3, 2017 with 63,613 vested on November 3, 2019, 180,000 vested on each of November 1, 2020 and November 1, 2021 and 116,389 vested on November 1, 2022.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION